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The limitations of estimates of glomerular filtration rate
(GFR) based only on serum creatinine measurements have
spurred an interest in more sensitive markers of GFR.
Beta-trace protein (BTP), a low-molecular-weight
glycoprotein freely filtered through the glomerular basement
membrane and with minimal non-renal elimination,
may be such a marker. We have recently derived two GFR
estimation equations based on BTP. To validate these
equations, we measured BTP and the plasma clearance of
99mTc-DTPA in 92 adult kidney transplant recipients and 54
pediatric patients with impaired kidney function. GFR was
estimated using the serum creatinine–based Modification of
Diet in Renal Disease (MDRD) Study equation for adults, the
Schwartz and updated Schwartz equations in children, and 4
novel BTP-derived equations (our 2 equations and 2
proposed by Poge). In adults, our BTP-based equations had
low median bias and high accuracy such that 89–90% of
estimates were within 30% of measured GFR. In children, the
median bias of our 2 equations was low and accuracy was
high such that 78–83% of estimates were within 30% of
measured GFR. These results were an improvement
compared to the MDRD and Schwartz equations, both of
which had high median bias and reduced accuracy. The
updated Schwartz equation also performed well.
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Serum creatinine is a crude marker of glomerular filtration
rate (GFR) with several well-described limitations.1,2 It can
be noted that its serum concentration is dependent on
various non-renal factors, such as muscle mass and turnover,
medication use, diet, and non-renal elimination.1 GFR
estimation equations derived from serum creatinine have
repeatedly been shown to be inaccurate, particularly in
patient groups that are distinct from those in whom the
equations were derived such as kidney transplant recipi-
ents,3–5 patients with abnormal body composition,6 liver
dysfunction,7 or relatively well-preserved kidney function.8,9
This is presumably due to the influence of the myriad of
factors that affect creatinine production and non-glomerular
excretion, which are not adequately ‘corrected for’ in the
estimation equations. In the pediatric population, studies
have also documented the poor performance of creatinine-
based GFR estimates.10–12 An ‘updated’ Schwartz equation
based on serum creatinine has recently been described, but
has not yet been validated in an independent pediatric
population.13
Beta-trace protein (BTP) has emerged as an alternate
endogenous marker of GFR.14 It is a low-molecular-weight
glycoprotein with 168 amino acids that is filtered through the
glomerular basement membrane.15 It appears to have
minimal non-renal elimination.16 Since its first description
as a marker of impaired renal function in 1997,17 BTP has
been shown to be a more sensitive marker of GFR than
creatinine in patients with chronic kidney disease,18–21 in
kidney transplant recipients,22 and in children.19
Until recently, the absence of an equation to convert its
serum concentration into an estimate of GFR has limited the
clinical utility of BTP. We have recently proposed two GFR
estimation equations based on serum BTP (Table 1).23 These
were derived from a cohort of 163 kidney transplant
recipients (mean age: 53±12 years, 67% men, 90% white),
with a mean GFR of 59±23ml per min per 1.73m2. The
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purpose of this study was to validate these novel BTP-based
equations in two independent patients groups consisting of a
cohort of adult kidney transplant recipients and a cohort of
children with impaired kidney function. The performance of
the two BTP-based GFR estimation equations recently
proposed by Poge et al.24 and of the updated Schwartz
equation13 was also examined.
RESULTS
Patient characteristics
The clinical characteristics of the study groups are shown in
Table 2. The adult cohort had an average age of 53±13 years
and a median GFR of 51 (interquartile range (IQR) of 28)ml
per min per 1.73m2 (range: 11–99). All five stages of chronic
kidney disease are represented.25 The pediatric cohort had an
average age of 10±5 years and a median GFR of 69 (IQR of
38)ml per min per 1.73m2 (range: 16–97).
Equation performance
The concordance correlation coefficients between the mea-
sured GFR and the estimation equation GFR are shown in
Table 3. In adults, these were the strongest for the White BTP
equations. In children, concordance was strongest for the
updated Schwartz equation followed by the two White BTP
equations. Table 4 shows the performance of the estimation
equations. In the adult population, the bias of the White BTP
equations was significantly lower than those of the four-
variable Modification of Diet in Renal Disease (MDRD),
Poge BTP1, and Poge BTP2 equations (Po0.0001 for all
comparisons). They were highly accurate with 89 and 90% of
estimates within 30% of the measured GFR for White BTP1
and White BTP2 equations, respectively. In comparison, the
four-variable MDRD Study and Poge equations had higher
negative bias and had lower accuracy with only 76, 76 and
65% of estimates within 30% of the measured GFR,
respectively. The 30% accuracy of the White BTP1 equation
was significantly higher than that of the Poge BTP1
(P¼ 0.012) and Poge BTP2 (Po0.0001) equations. The
30% accuracy of the White BTP2 equation was significantly
higher than that of the four-variable MDRD Study equation
(P¼ 0.01), Poge BTP1 (P¼ 0.007), and Poge BTP2
(Po0.0001) equations.
The performance analysis was repeated after subdividing
patients by GFR greater (n¼ 49) or less (n¼ 43) than the
median of 51ml per min per 1.73m2 (Table 5). Equation
performance varies considerably between the subgroups,
particularly for the Poge and MDRD Study equations with
substantially increased underestimation (negative bias) of
GFR with improved graft function. The White BTP equations
Table 2 | Patient characteristicsa
Characteristic
Adult cohort
(n=92)
Pediatric
cohort (n=54)
Male (n (%)) 62 (68) 32 (59)
Age (years) 53±12 10±5
Race (n (%))
White 87 (95) NA
Black 2 (2) NA
Other 3 (3) NA
Weight (kg) 85.9±22.7 37.9±22
Height (cm) 169.3±10.2 133.1±31
Body surface area (m2) 1.96±0.26 1.16±0.43
Medication (n (%))
Prednisone 85 (92) NA
Calcineurin inhibitor 88 (96) NA
Sirolimus 4 (4) NA
Mycophenolate mofetil 63 (68) NA
Azathioprine 17 (18) NA
Serum creatinine (mmol/l) 144±70 106±68
Serum urea (mmol/l) 10±7 9±6
Serum BTP (mg/l) 1.29±0.71 1.67±1.12
Median DTPA GFR (ml per min per 1.73m2)
(IQR)
51 (28) 69 (38)
CKD stage by measured GFR (n (%))
Stage 1, GFR X90ml per min per 1.73m2 2 (2) 8 (15)
Stage 2, GFR 60–89ml per min per 1.73m2 26 (28) 25 (46)
Stage 3, GFR 30–59ml per min per 1.73m2 49 (53) 12 (22)
Stage 4, GFR 15–29ml per min per 1.73m2 12 (13) 9 (17)
Stage 5, GFR o15ml per min per 1.73m2 3 (3) 0 (0)
BTP, beta-trace protein; CKD, chronic kidney disease; DTPA, diethylenetriaminepen-
taacetic acid; GFR, glomerular filtration rate; IQR, interquartile range; NA, data not
available.
aData expressed as mean±s.d. unless otherwise specified.
Table 3 | Concordance correlation coefficients
Equation Adults (95% CI) Pediatrics (95% CI)
4-Variable MDRD study 0.676 (0.577, 0.775) —
Schwartz — 0.681 (0.563, 0.800)
Updated Schwartz — 0.836 (0.757, 0.915)
White BTP1 0.829 (0.765, 0.893) 0.788 (0.676, 0.881)
White BTP2 0.819 (0.751, 0.886) 0.779 (0.676, 0.881)
Poge BTP1 0.621 (0.518, 0.724) 0.587 (0.456, 0.718)
Poge 2 BTP2 0.511 (0.397, 0.625) 0.699 (0.571, 0.827)
BTP, beta-trace protein; CI, confidence interval; MDRD, Modification of Diet in Renal
Disease.
Table 1 | Glomerular filtration rate (GFR) estimation
equationsa
Reference Formula
Whiteb GFR1=112.1BTP0.662 urea0.280 (0.880 if female)
GFR2=167.8BTP0.758 creatinine0.204 (0.871 if female)
Pogeb GFR1=89.85BTP0.5541urea0.3018
GFR2=974.31 BTP0.2594  creatinine0.647
Leveyc GFR=186 creatinine–1.154 age0.203 (0.742 if
female) (1.21 if black)
Schwartzc,d GFR=(k length)/creatinine, k=0.7 (boys X13), k=0.45
(infantso1), k=0.55 (all others)
Updated
Schwartzc,d
GFR=(0.413 length)/creatinine
aGFR in ml per min per 1.73m2.
bBTP in mg/l; urea in mmol/l; creatinine in mmol/l.
cCreatinine in mg per 100ml.
dLength in cm and creatinine in mg per 100ml.
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show a more consistent performance across the two
subgroups. Figure 1 shows the bias of each equation across
levels of estimated GFR.
In the pediatric group, the White BTP1 equation had
significantly lower bias than the Schwartz (Po0.0001) and
Poge BTP1 (Po0.0001), but not the Poge BTP2 (P¼ 0.42),
equations (Table 4). Similarly, the White BTP2 equation had
significantly lower bias than the Schwartz (Po0.0001) and
Poge BTP1 (Po0.0001), but not the Poge BTP2 (P¼ 0.15),
equations. There were no significant differences in bias
between the White BTP1 and BTP2 equations and the
updated Schwartz equations (P¼ 0.32, P¼ 0.79). The
accuracy of the White BTP equations was high with 78 and
83% of estimates within 30% of measured GFR for White
BTP1 and White BTP2 equations, respectively. In contrast,
only 48% of the Schwartz equation estimates and 50 and 72%
of the Poge equation estimates were within 30% of the
measured GFR. The updated Schwartz equation also showed
high accuracy with 85% of estimates within 30% of the
measured GFR. There were no significant differences in
accuracies between the White BTP, updated Schwartz, and
Poge BTP2 equations.
DISCUSSION
This study reveals that the novel White BTP-based GFR
estimation equations are accurate in both an adult and a
pediatric population and shows improved estimation perfor-
mance compared with the standard creatinine-based GFR
estimation equations.
To date, BTP has been studied to a limited extent in the
pediatric population. Filler et al.19 report that the reciprocal
of BTP had a significantly higher correlation with GFR than
that of serum creatinine, and that the diagnostic accuracy of
BTP was improved over creatinine for the detection of a GFR
o90ml per min per 1.73m2. The poor performance of the
Schwartz equation in this study confirms previous reports of
reduced accuracy in pediatric patients with impaired renal
function.10,11 Seikaly et al.11 showed that the Schwartz
equation overestimated GFR by 90% in children with a
GFR o50ml per min per 1.73m2. Grubb et al.10 report a
mean percent bias of 51%, and only 25% of estimates were
within 30% of measured GFR using the Schwartz equation in
a cohort of 85 children. Similar to our findings, in a recent
study Schwartz et al.12 found that the equation overestimated
the measured GFR by, on average, 12.2ml per min per
1.73m2 and postulated that this can been attributed to
Table 4 | Bias, precision, and accuracy of creatinine and BTP estimatesa
Accuracy (% within)
Median bias Precision (IQR) Median % bias Precision (IQR) Mean bias Precision (s.d.) 10% 30%
Adults
4-Variable MDRD 6.0 14.7 13.8 23.7 9.0 12.1 32 76
White BTP1 0.3 11.9 0.9 25.9 1.5 10.6 36 89
White BTP2 0.1 11.5 0.4 23.9 1.7 10.5 38 90
Poge BTP1 9.3 12.6 19.6 20.5 11.0 11.3 20 76
Poge BTP2 11.2 16.8 21.2 24.7 13.3 12.4 18 65
Pediatrics
Schwartz 15.5 22.5 30.2 36.2 18.6 17.0 17 49
Updated Schwartz 6.1 14.2 9.4 26 4.9 13.1 30 85
White BTP1 10.3 17.5 16.6 23.7 8.6 14.4 28 78
White BTP2 8.3 15.6 15.2 23.0 7.1 16.1 24 83
Poge BTP1 19.7 22.9 28.8 19.9 18.4 14.2 11 50
Poge BTP2 9.0 21.1 18.6 29.9 9.5 16.2 26 72
BTP, beta-trace protein; IQR, interquartile range; MDRD, Modification of Diet in Renal Disease; 99mTc-DTPA, 99mtechnetium-diethylenetriaminepentaacetic acid.
aBias was defined as the difference between the estimated and the measured (99mTc-DTPA) GFR (estimated GFR –measured GFR); percentage bias was defined as [estimated
GFR – measured GFR]/measured GFR 100; precision was defined as the IQR for the median bias and standard deviation of the mean bias; both precision and bias were
expressed as ml per min per 1.73m2; accuracy was defined as the proportion of estimates that were within 10 or 30% of the measured (99mTc-DTPA) GFR.
Table 5 | Bias and 30% accuracy by GFR subgroups (GFR
o51ml per min per 1.73m2, n=43; GFR 451ml per min per
1.73m2, n=49) in the adult kidney transplant cohort
Median bias
(ml per min per
1.73m2)
Percentage
within 30%
4-Variable MDRD study
GFRo51ml per min per 1.73m2 2.8 89
GFR451ml per min per 1.73m2 24.2 65
White BTP1
GFRo51ml per min per 1.73m2 2.9 84
GFR451ml per min per 1.73m2 4.9 94
White BTP2
GFRo51ml per min per 1.73m2 3.6 84
GFR451ml per min per 1.73m2 4.8 96
Poge BTP1
GFRo51ml per min per 1.73m2 3.6 81
GFR451ml per min per 1.73m2 14.8 71
Poge BTP2
GFRo51ml per min per 1.73m2 3.4 84
GFR451ml per min per 1.73m2 19.9 49
BTP, beta-trace protein; GFR, glomerular filtration rate; MDRD, Modification of Diet in
Renal Disease Study.
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differences in creatinine assays. The original Schwartz
equation was derived using creatinine measured using a Jaffe
reaction, whereas the creatinine measured in the current and
recent Schwartz studies were measured using enzymatic
methods that yield lower values.26 Recently, a novel
creatinine-based estimation equation derived using enzy-
matic methods was proposed by Schwartz et al.13 This report
is the first to validate it in an independent cohort of patients.
Creatinine was measured using enzymatic methodologies,
and the results show significantly improved performance
compared with the traditional Schwartz equation. The
performance of the BTP equations in the pediatric popula-
tion is also encouraging and warrants further examination in
other pediatric populations with varying degrees of impaired
kidney function.
There has been limited data reported on the use of BTP in
kidney transplant recipients. Poge et al.22 showed that at a
given GFR, BTP had a greater increase above the upper
reference value compared with creatinine, although the
diagnostic performance was similar by receiver operating
characteristic analysis. In a recent publication, Poge et al.24
report on the derivation and validation of BTP-based GFR
estimation equations in kidney transplant recipients. They
propose two equations, one that included serum urea and the
other serum creatinine. Similar to our work, the equation
containing BTP and urea (Poge BTP1) had a higher R2 and
improved performance when validated than that containing
BTP and creatinine (Poge BTP2). Furthermore, the Poge
BTP1 equation had a bias of only 0.43ml per min per 1.73m2
compared with the White BTP1 equation, which over-
estimated the measured GFR by 9.3ml per min per 1.73m2.
In this study, the Poge equation underestimated the
measured GFR by 11ml per min per 1.73m2 whereas the
White BTP1 equation only underestimated it by 1.2ml per
min per 1.73m2. Thus, in both studies, the White BTP1
equation provided estimates that are on average B10ml per
min per 1.73m2 higher than those calculated using the Poge
equation. Both equations were derived using plasma
diethylenetriaminepentaacetic acid (DTPA) clearance as the
reference standard, and both include BTP and urea. The
White equation also contains a gender-correcting factor that
did not improve the model fit of the Poge equation.24 It is
interesting to note that the model fit using BTP alone was
substantially higher in our derivation cohort (R2¼ 0.756)
than that in the Poge study (R2¼ 0.651).23,24 The final model
of White equation also had a higher R2 (0.81) compared with
the Poge BTP1 equation (0.714).23,24 Even without gender,
the White model had an R2 of 0.791, and thus more of the
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Figure 1 | Estimation equation bias according to level of estimated GFR in ml per min per 1.73m2. Bias was calculated by subtracting
the measured GFR from the estimated GFR and is expressed in ml per min per 1.73m2. The median bias is represented by the solid
line and the first and third quartiles by the dashed lines. BTP, beta-trace protein; GFR, glomerular filtration rate; MDRD, Modification of Diet
in Renal Disease Study.
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variability in GFR could be explained by BTP and urea in the
White model as opposed to the Poge model.
The differing results of this current analysis and the Poge
study24 can be attributed to several factors. First, differences
in populations may also be contributing to between study
variance. The adult study populations are similar in gender,
race, and age, but the derivation and validation cohorts of
Poge et al. have a considerably lower average GFR. The
performance of creatinine-based GFR estimation equations is
dependent on GFR level in both kidney transplant27,28 and
non-transplant populations.8,29 This is presumably due to
differences in creatinine production, renal handling of
creatinine, and non-renal creatinine elimination at different
levels of GFR. Similar to creatinine, the relationship between
urea and GFR is confounded by other influences such as
volume status,30 cyclosporine use,31 steroid usage,30 liver
disease,30 and nutritional state.30 Poge et al.24 examined the
difference in performance of the BTP-based estimation
equations in subgroups above and below 50ml per min per
1.73m2. They found a greater negative bias (5.81ml per
min per 1.73m2) in the higher GFR subgroup compared with
a positive bias of 3.05ml per min per 1.73m2 in the lower
GFR subgroup for the Poge BTP1 equation. They did not,
however, find a significantly different bias for the White
BTP1 equation in the two subgroups, although the accuracy
did improve in the higher GFR group.24 In our GFR
subgroup analysis (4 and o51ml per min per 1.73m2)
(Table 5), a striking difference in equation performance is
evident, particularly for the Poge and MDRD Study
equations that is similar to that observed by Poge. Overall,
the Poge and MDRD Study equations show improved
performance in the lower GFR subgroup, which more closely
approximates the GFR of the equations’ derivation and
validation cohorts.
Second, differences in calibration of the analyte (urea,
BTP, and creatinine) assays likely have an important role. The
effect of non-standardized creatinine calibration on creati-
nine-based GFR estimation equations has been well de-
scribed, and it has led to efforts to internationally harmonize
creatinine measurement using assays traceable to the gold
standard isotope dilution mass spectrometry (IDMS).32,33
Such efforts have not been attempted for urea, which can be
measured using a number of methods based on different
analytical principals.34 Details regarding the measurement of
urea are not provided by Poge et al.24 Both studies used a
Dade Behring immunonephelometric assay to measure BTP,
but the platforms on which they were measured were
different. To date, differences in BTP assay calibration have
not been examined. We modeled the effect of hypothetical
systematic changes in urea and BTP assays in our laboratory
on the bias of the White BTP1 equation in our adult cohort
(results not shown). White BTP1 estimates using 20% higher
BTP and urea values are very similar to those obtained using
the Poge BTP1 equation and the actual BTP and urea values.
Poge et al. did not evaluate the White BTP2 equation. Both
studies used assays referable to an IDMS creatinine in the
evaluation of the Poge BTP2 equation. Therefore, in theory,
the disparate Poge BTP2 estimates cannot be explained by
differences in creatinine assay calibration.
Third, differences in gold standard GFR technique may
also be contributing to the noted study differences. Although
both used plasma clearance of DTPA after a single injection,
the sampling strategy differed. Poge et al.24 sampled at 1 and
3 h, while we sampled at 2, 3 and 4 h. This may have an
impact on GFR measurement, particularly in patients with
significantly reduced kidney function where delayed sampling
has been shown to improve correlation between tracer
plasma and urinary clearance.35,36
The poor performance of the MDRD equation has been
well documented elsewhere in renal transplant recipients37 as
well as in other patients who differ from the cohort in whom
the equation was derived.8,9 It can be noted that the
equations significantly underestimate the GFR in patients
with well-preserved kidney8 or graft function,37 and mod-
ifications to the original equations to account for this are
being developed.
Despite higher average GFR values, the pediatric cohort
had a higher mean BTP concentration compared with the
adult kidney transplant patients. The independent effect of
age on serum BTP levels has not been fully explored. Filler
et al.19 did not find an association between BTP and age in a
cohort of pediatric patients with various renal diseases,
although there was no correction for GFR and all participants
were children. Our data may suggest that age does
independently effect on BTP concentrations, but this requires
further study. Immunosuppressant medications may also
influence BTP concentration, which could also explain the
differences observed between the two populations. This needs
further exploration in a larger cohort of patients. It is also
possible that more significant overestimation of GFR
occurred in the pediatric age group by virtue of their
increased susceptibility to GFR overestimation, with more
impaired GFRs when delayed samples (44 h) are not
performed. It is unlikely that other differences in measure-
ment techniques explain this finding given that BTP was
measured in the same laboratory using the same assay. In
addition, the GFR was measured using identical protocols
and tracers, although at different institutions.
Strengths of this study include the measurement of GFR
and all analytes on the same day, and the utilization of serum
creatinine values was calibrated to the Cleveland Clinic for
the analyses using the MDRD Study equation and of IDMS
traceable creatinine values for the analyses using the Poge
BTP2 equation. Limitations should be noted. First, the adult
validation population is very similar in terms of demo-
graphics and GFR range to the White equations’ derivation
cohort. This limits the ability to extrapolate our findings to a
less homogeneous population. Second, the population was
largely white and the performance of the equations in non-
white patients cannot be inferred. In addition, we did not
have information on race in our pediatric patients. Third,
both validation cohorts were relatively small in size, which
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limits the precision of our estimates. Fourth, BTP was
measured only once, which may impact our findings, as the
intra-patient variability of BTP has not yet been established.
Fifth, the reproducibility of BTP remains unknown. Sixth,
delayed sampling beyond 4 h was not carried out, which may
have led to overestimation of the true GFR in patients with
significantly reduced kidney function. Further studies using
delayed sampling are required. Finally, BTP is more expensive
and is not as commonly available as creatinine, which reduces
its appeal as a marker of GFR at this time.
In conclusion, this validation study has found that the
novel White BTP-based GFR estimation equations are
substantially more accurate in adult kidney transplant
recipients than accepted creatinine-based GFR estimation
equations. The results are also very encouraging in a smaller
single-center pediatric population with impaired kidney
function Discrepancies in accuracy and precision remain
between BTP equations developed at different institutions,
which may reflect differences in urea and BTP assay
calibration between laboratories, differences in reference
standard GFR measurements, and differences in patient
populations. More widespread adoption of these equations
will require further validation in larger and more diverse
patient groups.
METHODS AND MATERIALS
Study patients
Data for the adult group were obtained from patients recruited to
two studies. To study novel markers of GFR, 41 stable kidney
transplant recipients (o30 mmol/l difference in creatinine between
two most recent values) were recruited from the Ottawa Hospital at
least 6 months after transplant . Patients were excluded if they were
unable to provide informed consent, were pregnant or breastfeeding,
had one or more episodes of acute rejection within preceding 3
months, a life expectancy o3 months, or anticipated graft failure
within 3 months. These patients were not part of the White BTP
equation derivation set, but had their GFR and analytes measured
within the same study period (2004–2006), similar to those in the
derivation set.23 Data from an additional 51 patients were recruited
from a Canadian multicenter trial with GFR and analyte measure-
ment performed between 2006–2008 at study baseline. Inclusion
criteria include a four-variable MDRD study estimated GFR420ml
per min per 1.73m2, a time since transplant of at least 3 months,
and at least 200mg of proteinuria per day. Exclusion criteria are
described in detail elsewhere.38 There were no medication-related
exclusion criteria. The studies were approved by each facility’s
Research Ethics Board and all patients provided informed consent.
The pediatric study group consisted of 54 consecutive children with
various kidney diseases and impaired kidney function (GFR
o100ml per min per 1.73m2) who had been referred to the
Children’s Hospital of Eastern Ontario (CHEO) for a DTPA GFR
study and who had a BTP measured on the day of their DTPA GFR
as part of routine clinical care.
Laboratory assessment
For both groups, GFR was measured using plasma clearance of
radiolabeled 99mtechnetium-DTPA (99mTc-DTPA) through a single
injection and plasma sampling at 120, 180, and 240min after
injection.3 GFR was then corrected for standard body surface area
using the Dubois formula in adults39 and the Mosteller formula in
children.40 At the time of the 99mTc-DTPA GFR measurement, blood
was sampled for measurement of creatinine, urea, and BTP. BTP was
measured for both adult and pediatric cohorts using a nephelo-
metric assay on a BN Dade Behring ProSpec analyzer (Dade
Behring, Marburg, Germany) at the same laboratory. The total
analytical imprecision (intra-assay plus inter-assay) of the assay
calculated from two control materials with concentrations of 1.51
and 7.89mg/l was 2.33 and 6.5%. For the adult cohort, a modified
Jaffe reaction on a Beckman Coulter LX20 Pro Clinical System was
used to measure serum creatinine in the same laboratory with the
manufacturer’s reagents (Beckman Coulter, Brea, CA, USA).
Coefficients of variation (CV) for serum creatinine were 4.9% at
0.6mg per 100ml (55mmol/l), 1.7% at 1.7mg per 100ml (150 mmol/
l), and 1.3% at 6.8mg per 100ml (600 mmol/l). A Beckman Coulter
LX20 Pro Clinical System was also used to measure serum urea. The
CV for serum urea was 3.5% at 14.6mg per 100ml (5.2mmol/l),
1.9% at 37.8mg per 100ml (13.5mmol/l) and 1.7% at 66.1mg per
100ml (23.6mmol/l). For the pediatric group, creatinine was
measured using an enzymatic assay on the Vitros 250
Chemistry System (Ortho Clinical Diagnostics, Markham, ON,
Canada) using manufacturer’s reagents. CVs for serum creatinine
were 3% at 0.87mg per 100ml (77.6 mmol/l), 1.5% at 2.11mg per
100ml (186.8mmol/l), and 1% at 7.10mg per 100ml (628 mmol/l).
Urea was measured using an enzymatic assay on the Vitros 250
Chemistry System (Ortho Clinical Diagnostics) using manufac-
turer’s reagents. The CV for serum urea was 1.3% at 13.7mg per
100ml (4.9mmol/l), 1.6% at 35.5mg per 100ml (12.7mmol/l), and
1.2% at 61.0mg per 100ml (21.8mmol/l).
Analysis
Estimated GFR was calculated using the two new White BTP
equations23 and the Poge BTP equations24 in all participants; the
four-variable MDRD study equation41 in adults; and the Schwartz
equation;26 and updated Schwartz equation13 in children (Table 1).
For the four-variable MDRD study equation, creatinine values were
calibrated to the Cleveland Clinic as recommended.32,42 Briefly,
50 Ottawa Hospital samples (range 53–354mmol/l) were sent to the
Cleveland Clinic laboratory. Overall, there was excellent agreement
between both laboratories (correlation coefficient of 0.989). The
calibrated creatinine was calculated as follows: 1.076(Ottawa
Hospital serum creatinine value)7.35 mmol/l. For the Poge BTP2
equation, creatinine values adjusted to the IDMS standard were used
for the adult cohort.24,42 Fifty Ottawa Hospital samples (range:
35–500mmol/l) were analyzed using the ‘old’ calibrators (not
referenced to IDMS) and then re-analyzed using set points obtained
from the instrument manufacturer’s that would give IDMS-
compatible results. The following regression equation was obtained:
IDMS creatinine¼ 0.990(Ottawa Hospital serum creatinine va-
lue)6.02 mmol/l.
The evaluation of the performance of the prediction equations
was performed by calculating the bias, precision, and accuracy as
recommended in the National Kidney Foundation guidelines on
chronic kidney disease.25 Bias was presented as the difference
between the estimated GFR and the measured 99mTc-DTPA GFR
(estimated GFR–measured GFR) and the percentage difference
([estimated GFRmeasured GFR]/measured GFR 100). A nega-
tive bias indicates that the GFR is underestimated by the prediction
equation. Precision was defined as the IQR of the median bias and
the standard deviation of the mean bias.2 Accuracy was defined as
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the percentage of GFR estimates lying between 10 and 30% of the
measured GFR (using 99Tc-DTPA).2 Differences in equation bias
and accuracy were assessed using a Wilcoxon or McNemar’s test as
appropriate. To account for multiple comparisons, we used a
conservative Bonferroni correction factor.43 As we compared five
prediction equations in each cohort, we adjusted our overall a by 5
(overall a¼ 0.05/5¼ 0.01). Therefore, a P-value o0.01 was
considered statistically significant. Concordance correlation coeffi-
cients between the measured GFR and estimated GFR were also
calculated.44
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